1Q26 sharpened the setup for NTHI as NEO212 completed Phase 1 dose escalation, set a 610 mg RP2D, and now moves toward FDA alignment on a potentially pivotal Phase 2 and possible accelerated pathway. NEO100 is fully enrolled in Phase 2a, with an interim readout expected around August 2026. P&L was secondary as investors now have a clearer catalyst path. Current funding levels are low, however, we are encouraged by the $10.0M undrawn LOC as well as the Company’s proven ability to source funding, as seen in the January PIPE transaction. Lastly, we always appreciate seeing open market buying by insiders, and that sentiment is even stronger for small cap biotech’s.
